In Vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1596-1602

  Corral, M J ^a   Gonzalez Sanchez E ^a   Cuquerella, M ^a   Alunda, J M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLICIN; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTILEISHMANIAL AGENT;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CELL COUNT; CELL COUNTING; CELL DEATH; CELL DIVISION; CYTOTOXICITY ASSAY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; INFECTION RATE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SULFINIC ACIDS; TRYPANOCIDAL AGENTS;

EID: 84896869905     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00710-13     Document Type: Article

References (32)

1. Desjeux P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27:305-318. http://dx.doi.org/10.1016/j. cimid.2004.03.004. (Pubitemid 38842803)
2. Croft SL, Sundar S, Fairlamb AH. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:11-126. http://dx.doi.org/10.1128/CMR.19.1.111-126. 2006.
3. Alvar J, Croft SL, Olliaro P. 2006. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol. 61:224-274. http://dx.doi.org/10.1016/ S0065-308X(05)61006-8.
4. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873-882. http://dx.doi.org/10. 1038/nrmicro1748. (Pubitemid 47578388)
5. Woods DJ, Knauer CS. 2010. Discovery of veterinary antiparasitic agents in the 21st century: a view from industry. Int. J. Parasitol. 40:1177-1185. http://dx.doi.org/10.1016/j.ijpara.2010.04.005.
6. Seifert K. 2011. Structures, targets and recent approaches in antileishmanial drug discovery and development. Open Med. Chem. J. 5:31-39. http://dx.doi.org/10.2174/1874104501105010031.
7. Sundar S, Chatterjee M. 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123:345-352. (Pubitemid 43905574)
8. Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Torrado-Santiago S, Torrado JJ. 2005. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J. Drug Target. 13:225-233. http://dx.doi.org/10.1080/10611860500097107. (Pubitemid 41086287)
9. Ordóñez-Gutiérrez L, Espada-Fernández R, Dea-Ayuela MA, Torrado JJ, Bolás-Fernández F, Alunda JM. 2007. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int. J. Antimicrob. Agents 30:325-329. http://dx.doi.org/10.1016/j.ijantimicag.2007.05.013. (Pubitemid 47361711)
10. Van de Ven H, Paulussen C, Feijens PB, Matheeeussen A, Rombaut P, Kayaert P, Van den Mooter G, Weyenberger W, Cos P, Maes L, Ludwig A. 2012. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome. J. Control. Release 161:795-803. http://dx.doi.org/10.1016/j.jconrel.2012.05.037.
11. Cutler RR, Wilson P. 2004. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. Br. J. Biomed. Sci. 61:71-74. (Pubitemid 38879530)
12. Khodavandi A, Alizadeh F, Ramal NS, Sidik SM, Toman F, Sekawi Z, Jahromi MA, Ng KP, Chong PP. 2011. Comparison between efficacy of allicin and fluconazole against Candida albicans in vitro and in a systemic candidiasis mouse model. FEMS Microbiol. Lett. 315:87-93. http://dx.doi.org/10.1111/j.1574- 6968.2010.02170.x.
13. McClure DC, Noland LL, Zatyrka SA. 1996. Antileishmanial properties of Allium sativum extracts and derivatives. Acta Hortic. 426:183-191.
14. Waag T, Gelhaus C, Rath J, Stich A, Leippe M, Schirmeister T. 2010. Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg. Med. Chem. Lett. 20:5541-5543. http://dx.doi.org/10.1016/j. bmcl.2010.07.062.
15. Corral-Caridad MJ, Moreno I, Toraño A, Domínguez M, Alunda JM. 2012. Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum. Exp. Parasitol. 132:475-482. http://dx.doi.org/10.1016/j.exppara.2012.08.016.
16. Seifert K, Croft SL. 2006. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50:73-79. http://dx.doi.org/10.1128/AAC.50.1.73-79.2006. (Pubitemid 43042905)
17. Chou TC, Hayball M. 1996. CalcuSyn for Windows, Multiple-Drug Dose-Effect analyzer and manual. Biosoft, Cambridge, United Kingdom.
18. Chou TC. 2008. Preclinical versus clinical drug combination studies. Leuk. Lymphoma 49:2059-2080. http://dx.doi.org/10.1080/10428190802353591.
19. Plumb JA. 2004. Cell sensitivity assays: the MTT assay. Methods Mol. Med. 88:165-169. http://dx.doi.org/10.1385/1-59259-406-9:165.
20. Méndez S, Nell M, Alunda JM. 1996. Leishmania infantum: infection of macrophages in vitro with promastigotes. Int. J. Parasitol. 26:619-622. http://dx.doi.org/10.1016/0020-7519(96)00037-9. (Pubitemid 26273964)
21. Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53:3855-3859. http://dx.doi.org/10.1128/AAC.00548-09.
22. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A. 2007. Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol. Int. 56:3-7. http://dx.doi.org/10.1016/j.parint.2006.09.001.
23. Seifert K, Munday J, Syeda T, Croft S. 2011. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani. J. Antimicrob. Chemother. 66:850-854. http://dx.doi.org/10.1093/jac/dkq542.
24. Wiesner J, Henschker D, Hurchinson DB, Beck E, Jomaa H. 2002. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. 46:2889-2894. http://dx.doi.org/10. 1128/AAC.46.9.2889-2894.2002.
25. Fivelman QL, Adagu IS, Warhurst DC. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisin against drug-resistant strains of Plasmodium falciparum. Antimicrob. Agents Chemother. 48:4097-4102. http://dx.doi.org/10. 1128/AAC.48.11.4097-4102.2004. (Pubitemid 39434861)
26. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson ADM. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76:25-32. (Pubitemid 28254976)
27. Larabi M, Yardley V, Loiseau PM, Appel M, Legrand P, Gulik A, Bories C, Croft SL, Barratt G. 2003. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob. Agents Chemother. 47:3774-3779. http://dx.doi.org/10.1128/AAC.47.12.3774-3779.2003. (Pubitemid 37484987)
28. Rabinkov A, Miron T, Konstantinovski L, Wilchek M, Mirelman D, Weiner I. 1998. The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochim. Biophys. Acta 1379: 233-244. http://dx.doi.org/10.1016/S0304-4165(97)00104-9. (Pubitemid 28252900)
29. Ogita A, Fujita K-I, Tanaka T. 2009. Enhancement of the fungicidal activity of amphotericin B by allicin: effects on intracellular ergosterol trafficking. Planta Med. 75: 222-226. http://dx.doi.org/10.1055/s-0028-1088376.
30. Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, Pandey K, Ravidas V, Kumar M, De T, Singh D, Das P. 2012. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 56:1031-1041. http://dx.doi.org/10.1128/AAC.00030-11.
31. Miron T, Listowsky I, Wilchek M. 2010. Reaction mechanisms of allicin and allyl-mixed disulfides with proteins and small thiol molecules. Eur. J. Med. Chem. 45:1912-1918. http://dx.doi.org/10.1016/j.ejmech.2010.01.031.
32. Olliaro P. 2010. Drug combinations for visceral leishmaniasis. Curr. Opin. Infect. Dis. 23:595-602. http://dx.doi.org/10.1097/QCO.0b013e32833fca9d.